MicroRNAs (miRNAs) are small RNAs comprised of 20-25 nucleotides that regulate gene expression by inducing translational repression or degradation of target mRNA. The importance of miRNAs as a mediator of disease pathogenesis and therapeutic targets is rapidly emerging in neuroscience, as well as oncology, immunology, and cardiovascular diseases. In Parkinson’s disease and related disorders, multiple studies have identified the implications of specific miRNAs and the polymorphisms of miRNA target genes during the disease pathogenesis. With a focus on Parkinson’s disease, spinocerebellar ataxia, hereditary spastic paraplegia, and Huntington’s disease, this review summarizes and interprets the observations, and proposes future research topics in this field.

Key Words: MicroRNA, Parkinson’s disease, Spinocerebellar ataxia, Hereditary spastic paraplegia, Huntington’s disease.

What is a microRNA?

MicroRNAs (miRNAs) are small, non-coding RNAs comprised of 20-25 nucleotides that regulate expression by blocking translation or direct degradation of target messenger RNAs (mRNAs). miRNAs target genes through sequence-specific hybridization to the 3’ untranslated region (UTR) of mRNAs. miRNAs were first discovered in Caenorhabitis elegans by Dr. Victor Ambros and colleagues in 1993, and have now been identified in almost every species, including humans.

During the last decade, a number of notable studies have identified the biogenesis and regulatory pathway of miRNA. In brief, miRNA genes are transcribed by RNA polymerase II into double-stranded primary miRNA (pri-miRNA), which forms a hairpin-like structure and a double-stranded RNA-specific nuclease cleavage signal. This pri-miRNA is processed by the Dorsa/DGCR8 ribonuclease complex to form a pre-miRNA. The pre-miRNA is exported into the cytoplasm by a nuclear export protein (Exportin 5). Then, the pre-miRNA is cleaved by a dicer enzyme into 20-25 nucleotide double-stranded mature miRNA. The double strands are composed of a guide (the effective strand that binds to the target mRNA) and a passenger strand. The guide single-strand miRNA assembles into a protein-RNA complex [RNA-induced silencing complex (RISC)], and targets mRNA by base pairing. At the 5’ region of miRNA, 7-8 sequences make up the “seed” sequence, which is critical for base pairing between miRNA and target mRNA. The seed sequences are annealed with a 3’ UTR of target mRNA. Although seed-target binding needs uninterrupted complementarities, additional weak binding between the 3’ end of miRNA and the target sequences do not require perfect complementarities, which is why one miRNA can regulates hundreds of mRNAs.

MiRNAs play an integral role in most physiologic phenomena and diseases, such as the immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation, and development. Recent studies are providing new evidence that miRNA also plays an important role in the central nervous system (CNS); indeed, the expression and functions of miRNAs are altered in various CNS diseases. For instance, the loss of Dicer, a key regulator of miRNA biogenesis, induces neurodegeneration of the striatum and cerebellum, suggesting roles in neurodegenerative diseases. Accordingly, miRNA-based pathogenesis and drug
development highlighted the opening of a new field in biomedical and neuroscience. In addition, analysis of miRNA-related molecules can provide novel clinical insight. For example, low levels of Dicer and Drosha miRNA in ovarian cancer cells have associations with poor outcomes in patients with ovarian cancer.\(^1\)

In this review, we have focused on the role and possible research topics of selective miRNAs in Parkinson’s disease (PD), and related disorders.

**MiRNAs Implicated in PD and Related Disorders**

**PD**

MiRNA function is important for the maintenance of midbrain dopaminergic neurons. For example, the deletion of Dicer, the key enzyme during miRNA biogenesis, leads to the progressive loss of midbrain dopaminergic neurons.\(^3\) PD brains have different subsets and profiles of miRNA expression compared to other neurodegenerative diseases, such as Alzheimer’s disease.\(^4,5\) One of the key miRNAs regulated in the dopaminergic cells is miR-133b, which was reported to be expressed in the midbrain dopaminergic neurons and deficient in midbrain tissues of PD patients, although only 5 controls and 3 PD brains were examined.\(^6\) A transcription factor, Pitx3 mRNA, is suppressed by miR-133b (Pitx3 protein enhances the transcription of miR-133b), showing a reciprocal feedback between Pitx3 and miR-133b (Figure 1A). Identifying single nucleotide polymorphisms (SNPs) in miR-133b and Pitx3 genes\(^11\) has failed to observe any risk alleles in the genes associated with PD. Accordingly, the acquired transcriptional changes in miR-133b expression might be more important than the genetic variability in the pathogenesis of PD.

The expression of \(\alpha\)-synuclein is repressed by miR-7 by targeting 3' UTR of the \(\alpha\)-synuclein mRNA \textit{in vitro}.\(^12\) The down-regulation of \(\alpha\)-synuclein by miR-7 protects cells from oxidative damage, and 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridinium (MPTP)-induced Parkinson mice have reduced miR-7 levels.\(^12\) In addition, miR-153 also reduces \(\alpha\)-synuclein translation in neuronal cultures.\(^13\) Figure 1B shows the possible interaction between the \(\alpha\)-synuclein gene (SNCA) and miRNAs predicted by the TargetScan program.\(^14\)

Mutation of leucine-rich repeat kinase 2 (LRRK2) causes familial and sporadic PD, and accounts for several PD cases.\(^15\) According to a recent discovery, mutation of LRRK2 is associated with dysfunctional machinery of miRNA-mediated translational repression (Figure 1C). Mutant LRRK2 antagonizes let-7 and miR-184 miRNAs, leading to the overproduction of the targets (E2F1/DP).\(^16\) E2F1 and DP are components of the transcriptional regulator complex, the overproduction of which may lead to abortive cell division and death of dopaminergic neurons.\(^16\)

Another genetic issue involves SNPs found in a miRNA binding site. Polymorphisms of fibroblast growth factor 20 (FGF20) have been associated with the increased risk of PD,\(^17\) and FGF20 is highly expressed in substantia nigra pars compacta.\(^18\) In the 3' UTR of the FGF20 gene, one SNP (rs-12720208, C→T) disrupts a binding site of miR-433, increasing the translation of FGF.\(^19\) The increased FGF20 leads to \(\alpha\)-synuclein overexpression, which corresponds to the pathologic process of PD.\(^19\) Indeed, T allele carriers of SNP rs-12720208 are at increased risk of PD.\(^19\) In addition, T allele carriers of SNP rs12720208 have diminished verbal episodic memory and a steeper decrease in hippocampal volume observed in MRI.\(^20\) However, another study did not reproduce the influence of FGF20 rs12720208 SNP and miR-433 variation on PD in a separate population.\(^21\) Although further studies are necessary, SNP information from genome-wide analysis might provide insights regarding disease risks, prognoses, and drug responses.

**Spinocerebellar ataxia**

A few studies have investigated the role of miRNAs in spinocerebellar ataxia (SCA). Although each patient with SCA has responsible mutant genes and miRNAs may not be the cause of the disease, miRNAs can be a mediator of the pathogenesis. For example, miR-19, miR-101, and miR-130 regulate ataxin1 levels, and inhibition of the miRNAs increases the neurotoxicity of polyglutamine-expanded ataxin1 \textit{in vitro}.\(^22\) It is also known that miR-144 represses ataxin1 \textit{in vitro} and is reduced in the cerebellum of SCA1 patients.\(^23\) In \textit{Drosophila},
miRNA-bantam and additional miRNAs are involved in mitigating polyQ-induced neurodegeneration in a SCA3 model. In *Drosophila*, miR-8 targets atrophin-1, which is responsible for dentatorubral and pallidolysian atrophy (DRPLA), preventing neurodegeneration. Research involving miRNAs in SCA and cerebellar degeneration are preliminary and await further investigation.

**Hereditary spastic paraplegia**

Hereditary spastic paraplegia (HSP) is characterized by degenerative corticospinal tract axons that lead to progressive lower limb spastic paralysis. HSP is genetically heterogeneous, including autosomal dominant, autosomal recessive, and X-linked forms. The autosomal dominant form is the most frequent form, and mutations in spastin (SPG4) and atlastin (SPG3A) genes account for approximately 50% of the cases. Recently, novel mutations in the REEP1 gene have been reported in autosomal dominant HSP patients. Interestingly, three point mutations in 3' UTR of REEP1, which is likely to be a binding site of miR-140 or miR-691, have been observed. The incidence of these mutations is very low; only 2 cases with mutations in 3' UTR of REEP1 gene were observed in 535 unrelated cases. Nevertheless, these studies suggest that mutations in the miRNA binding sites can be a responsible locus of genetic disorders and the hidden mutations can cause disease phenotypes.

**Huntington's disease**

Huntington's disease (HD) is caused by the abnormal expansion of CAG repeats in *huntingtin*, resulting in the loss of medium spiny neurons in the striatum, involuntary choreiform movements, progressive cognitive impairment, and neuropsychiatric symptoms. Although the responsible gene is defined, a number of miRNAs participate in the pathogenesis of abnormal CAG repeats. HD transgenic mice have altered expression of miRNA biogenesis enzymes, including drosha and dicer. Importantly, dicer-knockout mice have behavioral and neuroanatomic phenotypes of striatal degeneration and Huntington's disease.

A number of alterations in miRNA expression have been detected in HD human brains and transgenic mice. In HD, enhanced interaction between RE1 transcriptional regulatory regions and RE1 silencing transcription factor (REST) causes transcriptional dysfunction. Normal wild-type huntingtin inhibits the silencing activity of REST, and mutant huntingtin loses its control, resulting in increased binding of REST/ neuron restricted silencer factor to RE1 neuron restrictive silencer element, which causes persistent transcriptional dysfunction. In brain tissues of HD patients, miR-9/9*, miR-29b, miR-124a, and miR-132 are downregulated by uncontrolled enhanced action of REST, and miR-9 and -9* are controlled by the REST-RE1 interaction, they form a double feedback loop. In addition, miR-124 is expressed at a low level in the brains of HD patients and transgenic mice. Adult neurogenesis in the subventricular zone (SVZ) is enhanced by miR-124 in normal mice, and the dynamics of SVZ neurogenesis are altered in HD mice. Although we know the abnormal gene in HD, future research in miRNA might add to our knowledge about what mediates the neurotoxicity of abnormal CAG expansion.

**Future Research Topics**

**Modulation of miRNA**

Key miRNAs involved in the pathogenesis can be therapeutic targets. Thus, up-regulated miRNAs can be inhibited by antisense neutralizing oligonucleotides (antagomir), and down-regulated miRNAs can be delivered to the tissue and organ by using viral vectors or miRNAs themselves. Among these two options, the former is emerging as a hot topic in the drug development. The antagomirs can be generated by 2’O-methylated or locked nucleic acid-based antisense oligonucleotides. These antagomirs are resistant to RNase-induced degradation, reach target tissues, and penetrates the cell membrane when delivered systemically. Meanwhile, naked miRNAs are vulnerable to RNase-induced degradation and a single miRNA can repress the production of hundreds of proteins. Antagomirs targeting the upregulated, abnormally-altered, and corresponding miRNAs in neurodegenerative diseases have high specificity for target binding, and thus warrant active research in the field.

**SNP study**

We have discussed that SNP or point mutations at 3' UTR of miRNA-binding sites might increase disease risks. Another interesting loci that needs screening for SNPs or point mutations are promoter sequences of miRNA genes. The mechanism which governs the expression of miRNAs has not been fully understood. Although mature miRNAs are generated by a series of enzymatic processing and regulatory factors for the enzymes have been suggested, transcription, degradation, and epigenetic factors influence the final level of each miRNA. Accordingly, analysis of respective promoter regions of a selected miRNA might reveal an important locus of responsible genes for the neurodegenerative diseases. A more detailed discussion on this topic has been the subject of a recent review.

**Development of biomarkers based on miRNA**

MicroRNAs can be used as biomarker of CNS disorders. Enhanced miRNAs in the brain can be released into the circulating blood and detected. The circulating miRNAs are substantially stable from degradation and have been reported as promising biomarkers in various disease conditions. For example, the concentration of a brain-specific miRNA (miR-124)
is increased in the plasma of rats with acute stroke.⁴⁰ The plas-
ma level of miR-134 is associated with the severity of manic
symptoms of patients with bipolar disorder.⁴¹ Patients with
traumatic brain injury have altered plasma miRNA levels.⁴²
The method for precise measurement of miRNAs in circu-
lating blood has been developed.⁴³ In addition, miRNAs in cer-
ebrosial fluid (CSF) can provide putative biomarkers for di-
agnostic uses in neurodegenerative diseases.⁴⁴ Accordingly,
the measurement of circulating or CSF miRNAs in patients
with movement disorders might be useful for diagnosis, pre-
diction of prognosis, and estimation of drug responses.

Conclusion

Active miRNA research emerged less than a decade ago.
Moreover, findings on the role of miRNA in neurodegenera-
tive diseases and movement disorders have been reported
since a few years ago. Although RNA-based approaches have
not completely elucidated the pathogenesis of the diseases, it
is clear that miRNA research has considerable appeal, provid-
ing new ideas on pathogenesis, candidate genetic markers,
and therapeutic modalities. It is now up to physicians and neurobi-
ologists to determine the clinical implications of miRNAs.

Acknowledgments

This work was supported by grants from the Korea Health 21 R&D Proj-
et, Ministry of Health & Welfare (A092058), and WCU Neurocytomics,
South Korea. S-T.L. was supported by a grant of the Korea Healthcare
Technology R&D Project (A100548).

REFERENCES

1. Lee BC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene
lin-4 encodes small RNAs with antisense complementarity to lin-14.
Cell 1993;75:843-854.
2. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals.
Nat Rev Mol Cell Biol 2004;5:742-751.
3. Krol J, Loedige I, Filipowicz W. The widespread regulation of mi-
RNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-
610.
4. Selbach M, Schwannhäusser B, Thirerfelder N, Fang Z, Khanna R, Ra-
jewsky N. Widespread changes in protein synthesis induced by mi-
RNAs. Nature 2008;455:58-63.
5. Cuellar TL, Davis TH, Nelson PT, Loeb GB, Harfe BD, Ullian E, et al.
Dicer loss in striatal neurons produces behavioral and neuroanatomical
phenotypes in the absence of neurodegeneration. Proc Natl Acad Sci U
S A 2008;105:5614-5619.
6. Schaefer A, O’Carroll D, Tan CL, Hillman D, Sugimori M, Llinas R,
et al. Cerebellar neurodegeneration in the absence of microRNAs.
J Exp Med 2007;204:1553-1558.
7. Merritt WM, Lin YG, Han LY, Kanat AA, Spannuth WA, Schmandt R,
et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N
Engl J Med 2008;359:2641-2650.
8. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Marchion D, et al. A
MicroRNA feedback circuit in midbrain dopamine neurons. Science
2007;317:1220-1224.
9. Sethi P, Lukiw WJ. Micro-RNA abundance and stability in human
brain: specific alterations in Alzheimer’s disease temporal lobe neocor-
tex. Neurosci Lett 2009;459:100-104.
10. Askainen S, Rudagalvyte M, Heikkinen L, Louhizarita K, Lakso M,
Wong G, et al. Global microRNA expression profiling of Caenorhabdit-
is elegans Parkinson’s disease models. J Mol Neurosci 2010;41:210-
218.
11. de Mena L, Coto E, Cardo LF, Díaz M, Blázquez M, Ribacoba R, et
al. Analysis of the Micro-RNA-133 and PTEN3 genes in Parkinson’s
disease. Am J Med Genet B Neuropsychiatr Genet 2010;153B:1234-
1239.
12. Jarr E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Re-
pression of alpha-synuclein expression and toxicity by microRNA-n.
Proc Natl Acad Sci U S A 2009;106:13052-13057.
13. Doxakis E. Post-transcriptional regulation of alpha-synuclein expres-
sion by mir-7 and mir-153. J Biol Chem 2010;285:12726-12734.
14. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked
by adenosines, indicates that thousands of human genes are microRNA
targets. Cell 2005;120:15-20.
15. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, London S, et al.
Mutations in LRRK2 cause autosomal-dominant parkinsonism with
pleomorphic pathogenesis. Neuron 2004;44:601-607.
16. Gehlke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regu-
lates microRNA-mediated translational repression. Nature 2010;466:
637-641.
17. van der Walt JM, Nourreddine MA, Kittappa R, Hauser MA, Scott
WK, McKay R, et al. Fibroblast growth factor 20 polymorphisms and
haptotypes strongly influence risk of Parkinson disease. Am J Hum
Genet 2004;74:1121-1127.
18. Ohrnachi S, Watanabe Y, Mikami T, Kono N, Ibi T, Akaiki A, et al.
FGF-20, a novel neurotrophic factor, preferentially expressed in the
substantia nigra pars compacta of rat brain. Biochem Biophys Res
Commun 2000;277:355-360.
19. Wang G, van der Walt JM, Mayhew G, Li YJ, Züchner S, Scott WK,
et al. Variation in the microRNA-433 binding site of FGF20 confers risk
for Parkinson disease by overexpression of alpha-synuclein. Am J Hum
Genet 2008;82:283-289.
20. Lemaître H, Mattay VS, Sambaturo F, Verchinski B, Straub RE, Calli-
cott JH, et al. Genetic variation in FGF20 modulates hippocampal biol-
ogy. J Neurosci 2010;30:5992-5997.
21. de Mena L, Cardo LF, Coto E, Miar A, Diaz M, Corao AI, et al. FGF20
rs12720208 SNP and microRNA-433 variation: no association with
Parkinson’s disease in Spanish patients. Neurosci Lett 2010;479:22-25.
22. Lee Y, Samaco RC, Gaecher JH, Thaller C, Ort HT, Zoghbi HY. miR-
19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially
modulate SCA1 pathogenesis. Nat Neurosci 2008;11:1137-1139.
23. Persengiev S, Kondova I, Otting N, Koeppen AH, Bontrop RE. Ge-
nome-wide analysis of miRNA expression reveals a potential role for
miR-144 in brain aging and spinocerebellar ataxia pathogenesis. Neu-
robiol Aging 2010.
24. Bilen J, Liu N, Burnett BG, Pittman RN, Bonini NM. MicroRNA path-
ways modulate polyglutamine-induced neurodegeneration. Mol Cell
2006;24:157-163.
25. Karres JS, Hilgers V, Carrera I, Treisman J, Cohen SM. The conserved
miR-101 and miR-130 co-regulate ATXN1 levels to potentially
modulate SCA1 pathogenesis. Nat Neurosci 2008;11:1137-1139.
26. Soderblom C, Blackstone C. Traffic accidents: molecular genetic in-
sights into the pathogenesis of the hereditary spastic paraplegias. Phar-
macol Ther 2006;109:42-56.
27. Zuccato C, Belyaev N, Conforti P, Ooi L, Tartari M, Papadimou E, et
al. Widespread disruption of repressor element-1 silencing tran-
scription factor/neuron-restrictive silencer factor occupancy at its target
genes in Huntington’s disease. J Neurosci 2007;27:9762-9768.
28. Beetz C, Schläle R, Deconinck T, Tran-Viet KN, Zhu H, Kremer BP,
et al. REEP1 mutation spectrum and genotype/phenotype correlation in
hereditary spastic paraplegia type 31. Brain 2008;131:1078-1086.
29. Landles C, Bates GP. Huntington’s and the molecular pathogenesis of
Huntington’s disease. Fourth in molecular medicine review series.
30. Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, et al. Altered microRNA regulation in Huntington’s disease models. Exp Neurol 2011; 227:172-179.

31. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington’s disease. J Neurosci 2008;28:14341-14346.

32. Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ. A microRNA-based gene dysregulation pathway in Huntington’s disease. Neurobiol Dis 2008;29:438-445.

33. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003;35:76-83.

34. Cheng LC, Pastrana E, Tavazoie M, Doetsch F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci 2009;12:399-408.

35. Phillips W, Morton AJ, Barker RA. Abnormalities of neurogenesis in the R6/2 mouse model of Huntington’s disease are attributable to the in vivo microenvironment. J Neurosci 2005;25:11564-11576.

36. Elmén J, Lindow M, Schätz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-899.

37. Elmén J, Lindow M, Silhataroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008;36:1153-1162.

38. Davis BN, Hata A. Regulation of MicroRNA Biogenesis: A miRiad of mechanisms. Cell Commun Signal 2009;7:18.

39. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-10518.

40. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009;55:1977-1983.

41. Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP, et al. MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res 2011;45:92-95.

42. Redell JB, Moore AN, Ward NH 3rd, Hergenroeder GW, Dash PK. Human traumatic brain injury alters plasma microRNA levels. J Neurotrauma 2010;27:2147-2156.

43. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010;107:677-684.

44. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 2008;14:27-41.